
    
      The study was terminated early when the results from Study 11961 (NCT00300885), an earlier
      Phase 3 study evaluating the effects of Sorafenib in combination with paclitaxel and
      carboplatin in subjects with advanced NSCLC, showed an overall lack of efficacy of Sorafenib
      in combination with paclitaxel and carboplatin in NSCLC and increased mortality in subjects
      with squamous subtype.
    
  